Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective.

IF 2.1 Q2 UROLOGY & NEPHROLOGY International Journal of Nephrology and Renovascular Disease Pub Date : 2024-01-03 eCollection Date: 2024-01-01 DOI:10.2147/IJNRD.S430532

Ahmed Fathi Elkeraie, Saeed Al-Ghamdi, Ali K Abu-Alfa, Torki Alotaibi, Ali Jasim AlSaedi, Abdulkareem AlSuwaida, Mustafa Arici, Tevfik Ecder, Mohammad Ghnaimat, Mohamed Hany Hafez, Mohamed H Hassan, Tarik Sqalli

{"title":"Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective.","authors":"Ahmed Fathi Elkeraie, Saeed Al-Ghamdi, Ali K Abu-Alfa, Torki Alotaibi, Ali Jasim AlSaedi, Abdulkareem AlSuwaida, Mustafa Arici, Tevfik Ecder, Mohammad Ghnaimat, Mohamed Hany Hafez, Mohamed H Hassan, Tarik Sqalli","doi":"10.2147/IJNRD.S430532","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic kidney disease (CKD) is a major public health concern in the Middle East and Africa (MEA) region and a leading cause of death in patients with type 2 diabetes mellitus (T2DM) and hypertension. Early initiation of sodium-glucose cotransporter - 2 inhibitors (SGLT-2i) and proper sequencing with renin-angiotensin-aldosterone system inhibitors (RAASi) in these patients may result in better clinical outcomes due to their cardioprotective properties and complementary mechanisms of action. In this review, we present guideline-based consensus recommendations by experts from the MEA region, as practical algorithms for screening, early detection, nephrology referral, and treatment pathways for CKD management in patients with hypertension and diabetes mellitus. This study will help physicians take timely and appropriate actions to provide better care to patients with CKD or those at high risk of CKD.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10771977/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nephrology and Renovascular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/IJNRD.S430532","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Chronic kidney disease (CKD) is a major public health concern in the Middle East and Africa (MEA) region and a leading cause of death in patients with type 2 diabetes mellitus (T2DM) and hypertension. Early initiation of sodium-glucose cotransporter - 2 inhibitors (SGLT-2i) and proper sequencing with renin-angiotensin-aldosterone system inhibitors (RAASi) in these patients may result in better clinical outcomes due to their cardioprotective properties and complementary mechanisms of action. In this review, we present guideline-based consensus recommendations by experts from the MEA region, as practical algorithms for screening, early detection, nephrology referral, and treatment pathways for CKD management in patients with hypertension and diabetes mellitus. This study will help physicians take timely and appropriate actions to provide better care to patients with CKD or those at high risk of CKD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

钠-葡萄糖共转运体-2 抑制剂在慢性肾病治疗中的影响：中东和非洲视角》。

慢性肾脏病（CKD）是中东和非洲地区（MEA）的主要公共卫生问题，也是 2 型糖尿病（T2DM）和高血压患者的主要死因。由于钠-葡萄糖共转运体-2 抑制剂（SGLT-2i）具有保护心脏的特性和互补的作用机制，因此在这些患者中尽早开始使用钠-葡萄糖共转运体-2 抑制剂（SGLT-2i）并与肾素-血管紧张素-醛固酮系统抑制剂（RAASi）进行适当的排序可能会带来更好的临床疗效。在本综述中，我们介绍了中东欧地区专家基于指南的共识建议，作为高血压和糖尿病患者慢性肾脏病管理的筛查、早期检测、肾脏病转诊和治疗路径的实用算法。这项研究将帮助医生及时采取适当行动，为慢性肾脏病患者或慢性肾脏病高危人群提供更好的护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Nephrology and Renovascular Disease UROLOGY & NEPHROLOGY-

CiteScore

3.90

自引率

5.00%

发文量

审稿时长

16 weeks

期刊介绍： International Journal of Nephrology and Renovascular Disease is an international, peer-reviewed, open-access journal focusing on the pathophysiology of the kidney and vascular supply. Epidemiology, screening, diagnosis, and treatment interventions are covered as well as basic science, biochemical and immunological studies. In particular, emphasis will be given to: -Chronic kidney disease- Complications of renovascular disease- Imaging techniques- Renal hypertension- Renal cancer- Treatment including pharmacological and transplantation- Dialysis and treatment of complications of dialysis and renal disease- Quality of Life- Patient satisfaction and preference- Health economic evaluations. The journal welcomes submitted papers covering original research, basic science, clinical studies, reviews & evaluations, guidelines, expert opinion and commentary, case reports and extended reports. The main focus of the journal will be to publish research and clinical results in humans but preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies and interventions.